GlassScriptPhysician profile
Robert Cavaliere
NPI 1730263096
$10,086.07
in general payments reported to CMS, 2019-2025
11 companies · $650 in 2025
The $650 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $97.84 · 2021: $111 · 2022: $233 · 2023: $7,949 · 2024: $756 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,720 · Food and Beverage: $1,579 · Travel and Lodging: $904 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,720.00 |
| Food and Beverage | $1,579.04 |
| Travel and Lodging | $903.90 |
| Education | $151.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $7,858.04 | 2023-2025 | |
| Novocure INC. | $1,601.61 | 2019-2025 | Optune, Optune Gio |
| Telix Pharmaceuticals | $225.65 | 2023-2025 | Illuccix |
| Alexion Pharmaceuticals, INC. | $169.00 | 2022-2024 | Ultomiris |
| Gt Medical Technologies, INC | $120.19 | 2025 | Gammatile |
| Abbott Laboratories | $58.01 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.37 | 2025 | |
| Springworks Therapeutics, INC. | $18.85 | 2025 | Gomekli |
| Zimmer Biomet Holdings, INC. | $13.35 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cavaliere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.